Infusion therapy for pneumonia: what’s new?

Authors

  • V.V. Nikonov Kharkiv Medical Academy of Postgraduate Education of the Ministry of Health of Ukraine, Kharkiv, Ukraine
  • K.I. Lyzohub Kharkiv Medical Academy of Postgraduate Education of the Ministry of Health of Ukraine, Kharkiv, Ukraine
  • M.V. Lyzohub State Institution “Sytenko Institute of Spine and Joint Pathology of the National Academy of Medical Sciences of Ukraine”, Kharkiv, Ukraine

DOI:

https://doi.org/10.22141/2224-0586.16.2.2020.203138

Keywords:

review, pneumonia, infusion therapy, septic shock

Abstract

Due to the increasing incidence of pneumonia, its severe course and the development of complications, its mixed viral and bacterial etiology, as well as declaration of COVID-19 a pandemic by the World Health Organisation, modern guidelines have been developed on the clinical picture, course, treatment, respiratory support and rehabilitation of patients with COVID-19. The difference in the course of severe pneumonia is the rapid development of acute respiratory distress syndrome on the background of immunodeficiency. The data of the literature review on the treatment of patients with pneumonia are presented: views on the need for infusion therapy and its complications, the use of vasopressors. Data on the treatment of patients with endogenous intoxication syndrome and clear indications for the use of sympathomimetics in septic shock are given. These studies have shown that the use of Rheosorbilact in combination therapy reduces the incidence of acute respiratory distress syndrome, the volume of infusion required to stabilize hemodynamics, promotes the movement of fluid from the interstitium to the bloodstream, helps remove excess fluid, reduces the level of major markers of intoxication. Such properties of Rheosorbilact indicate a positive effect of its use in the comprehensive treatment of pneumonia and septic shock.

Downloads

Download data is not yet available.

References

Klepikov І. Acute Pneumonia and Intravenous Infusion. Ped. Health Res. 2017. 2. 1. doi: 10.2176/2574-2817.100011.

Johns Hopkins University and Medicine COVID-19 map. Johns Hopkins Coronavirus Resource Centre. URL: https://coronavirus.jhu.edu/map.html. Date accessed: April 25, 2020.

Wu Z., McGoogan J.M. Characteristics of and important lessons from the coronavirus disease 2019 (COVID-19) outbreak in China: summary of a report of 72 314 cases from the Chinese Center for Disease Control and Prevention. JAMA. 2020 (published online Feb 24). DOI:10.1001/jama.2020.2648.

Rosenstenge A., Lee Y.C.G. Pleural infection-current diagnosis and management. J. Thorac. Dis. 2012. 4. 186-193.

Посібник з профілактики та лікування COVID-19. 2020. 35 С. URL: https://healthcenter.od.ua/wp-content/uploads/2020/04/ posibnyk-covid-19-ukraine.pdf.

Burgdorff A.-M., Bucher M., Schumann J. Vasoplegia in patients with sepsis and septic shock: path ways and mechanisms. J. Int. Med. Res. 2018. 46(4). 1303-1310. PMID: 29332515. DOI: 10.1177/0300060517743836.

Malbrain M.L., Marik P.E., Witters I., Cordemans C., Kirkpatrick A.W., Roberts D.J., Van Regenmortel N. Fluid overload, deresuscitation, and outcomes in critically ill or injured patients: a systematic review with suggestions for clinical practice. Anaesthesiol. Intensive Ther. 2014. 46(5). 361-380. PMID: 25432556, DOI: 10.5603/AIT.2014.0060.

Сапичева Ю.Ю., Ливанцев В.В., Петровская Е.Л., Лопатин А.Ф. Тактика ведения пациентов с сепсисом и септическим шоком в многопрофильном стационаре. Москва, 2015. 35 с. ISBN 978-5-98511-299-3.

Arslantas M.K., Gul F., Kararmaz A., Sungur F., Ayanoglu H.O., Cinel I. Early administration of low dose norepinephrine for the prevention of organ dysfunctions in patients with sepsis. Intensive Care Med. Exp. 2015. 3(1). A417-418. PMCID: PMC4798466. DOI: 10.1186/2197-425X-3-S1-A417-418.

Сепсис: классификация, клинико-диагностическая концепция и лечение. Под редакцией академика РАН Б.Р. Гельфанда. 4-е изд., дополн. и перераб. Москва: Медицинское информационное агентство, 2017. ISBN 978-5-8948-1988-4.

Shin J.Y., Roh S.G., Lee K.M., Yang K.M. Ischemic Necrosis of Upper Lip, and All Fingers and Toes After Norepinephrine Use. J. Craniofac. Surg. 2016. 27(2). 453-454. PMID: 26854781. DOI: 10.1097/SCS. 0000000000002463.

Gattinoni L., Coppola S., Cressoni M. et al. COVID-19 does not lead to a “typical” acute respiratory distress syndrome. Am. J. Respir. Crit. Care Med 2020. doi: 10.1164/rccm.202003-0817LE.

Zangrillo A., Beretta L., Silvani P. et al. Fast reshaping of intensive care unit facilities in a large metropolitan hospital in Milan, Italy: facing the COVID-19 pandemic emergency. Crit. Care Resusc. 2020.

National Health Commission of the People’s Republic of China. Protocols for Prevention and Control of COVID-19 (6th version) [EB/OL]. (2020-03-09) [2020-0315]. URL: http://www.nhc.gov.cn/jkj/s3577/202003/4856d5b0458141fa9f376853224d41d7.shtml (in Chinese).

Jacob M., Chappel D., Hoffman-Kiefer K. et al. The intravascular volume effect of Ringer’s lactate is below 20 %: a prospective study in humans. Crit. Care. 2012. Vol. 16. R86.

Strunden M.S, Heckel K., Goetz A.E, Reuter D.A. Peri­operative fluid and volume management: physiological basis, tools and strategies. Ann. Intensive Care. 2011. 1. 2. Published online 2011 Mar 21. doi: 10.118.

Черний В.И., Колесников А.Н., Олейников К.Н. Рациональная инфузионная терапия. Донецк: Издатель Заславский А.Ю., 2012. С. 39.

Duchesne J.C., Simms E., Guidry C., Duke M, Beeson E., McSwain N.E. et al. Damage control immunoregulation: is there a role for low-volume hypertonic saline resuscitation in patients ma­naged with damage control surgery? Am. Surg. 2012. 78(9). 962-8.

Loftus T.J., Efron P.A., Bala T.M., Rosenthal M.D., Croft C.A., Smith R.S., Moore F.A., Mohr A.M., Braсkenridge S.C. Hypertonic saline resuscitation follow in emergent laparotomy and temporary abdominal closure. J. Trauma Acute Care Surg. 2018 Feb. 84(2). 350-357.

DuBose J.J., Kobayashi L., Lozornio A., Teixeira P., Inaba K., Lam L. еt al. Clinical experience using 5% hypertonic saline as a safe alternative fluid for use in trauma. J. Trauma. 2010. 68(5). 1172-7.

Orbegozo D., Vincent J.-L. Hypertonic Saline in Human Sepsis: A Systematic Review of Randomized Controlled Trials. June 2019. Vol. 128.

Waters J.H., Gottlieb A., Schoenwald P., Popovich M.J., Sprung J., Nelson D.R. Normal saline versus lactated Ringer’s solution for intraoperative fluid management in patients undergoing abdominal aortic aneurysm repair: an outcome study. Anesth. Analg. 2001. 93. 817-822. 10.1097/00000539-200110000-00004.

Skellett S., Mayer A., Durward A., Tibby S.M., Murdoch I.A. Chasing the base deficit: hyperchloremic acidosis following 0.9% saline fluid resuscitation. Arch. Dis. Child. 2000. 83. 514-516. 10.1136/adc.83.6.514

Gunnerson K.J., Saul M., He S., Kellum J.A. Lactate versus non-lactate metabolic acidosis: a retrospective outcome evaluation of critically ill patients. Crit. Care. 2006. 10. R22. 10.1186/cc3987.

Den Ouden D.T., Meinders A.E. Vasopressin: physiology and clinical use in patients with vasodilatory shock: a review. The Netherlands Journal of Medicine. 2005. 63. 4-13.

McCorry L.K. Physiology of the Autonomic Nervous System. Am. J. Pharm. Educ. 2007. 15. 71(4). 78.

Гуменюк Н.И. Сравнительная эффективность неогемодеза, сорбилакта и реосорбилакта в комплексной инфузионной дезинтоксикационной терапии. Сімейна медицина. 2004. № 2. С. 38-62.

Рижко О.О. Інфузійна терапія реосорбілактом. Укр. пульмонологічний журнал. 2002. № 1. С. 94-96.

Коваленко О.М. Лікування опікового шоку на спеціалізованому етапі. Клінічна хірургія. 2019 Серпень. 86(8). С. 13-19.

Курудимова А.А., Голынский Г.Ю., Додул А.П. Преимущества применения реосорбилакта в составе инфузионной терапии при проведении реваскуляризирующих операций при острой ишемии нижних конечностей. Український журнал гематології та трансфузіології. 2012. № 4. С. 233-234.

Інструкція до медичного застосування препарату Реосорбілакт. URL: https://compendium.com.ua/dec/267128.

Аваков В.Е., Сайипов Р.М., Давыдов Д.В. Детоксицирующие свойства препарата Реосорбилакт и его влияние на гемостаз. Медицина неотложных состояний. 2014. № 2(57). С. 47-51.

Капшитарь А.В. Реосорбилакт в программе консервативной терапии у больных с панкреонекрозом. Український хіміо­терапевтичний журнал. 2012. № 3(26). С. 78-80.

Published

2021-09-30

How to Cite

Nikonov, V., Lyzohub, K., & Lyzohub, M. (2021). Infusion therapy for pneumonia: what’s new?. EMERGENCY MEDICINE, 16(2), 31–36. https://doi.org/10.22141/2224-0586.16.2.2020.203138

Issue

Section

Scientific Review

Most read articles by the same author(s)

1 2 3 4 5 6 7 8 9 > >>